# Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine

> **NCT01005238** · PHASE4 · TERMINATED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 27 (actual)

## Conditions studied

- Hepatitis, Chronic

## Interventions

- **DRUG:** Lamivudine
- **DRUG:** Telbivudine

## Key facts

- **NCT ID:** NCT01005238
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2014-12
- **Final completion:** —
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** unsufficient patient recruitment
- **Last updated:** 2015-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01005238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01005238, "Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01005238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*